INTRODUCTION: We describe clinical features and prognostic factors of renal medullary carcinoma (RMC) by performing a pooled analysis of all reported cases since 1995. METHODS: A systematic search was performed to identify all articles describing patients with medullary renal cancer until February 2013. Survivals were estimated using Kaplan-Meier method with 95% confidence intervals and compared across the groups using the log-rank test. The following factors were evaluated using the Cox proportional hazards model: association of extension of disease at diagnosis, response to therapy, and surgical treatment of primary tumour with overall. RESULTS: A total 47 articles were selected; these described 165 patients with RMC plus 1 from our centre. The median age was 21 years and 98% of cases had the sickle cell trait. The mean size of the primary tumours was 6.0 cm, with an involvement of loco-regional lymph nodes in 71% of cases. The overall survival at diagnosis was 4.0 months in metastatic patients and 17.0 months in non-metastatic patients. Patients who received platinum-paclitaxel-gemcitabine had longer control of the disease when compared to topoisomerase inhibitors or targeted therapies. The multivariate analysis confirmed that the advanced stage at diagnosis increased the risk of death of about threefold. CONCLUSION: RMC is a tumour with poorer prognosis; based on these results, platinum-based chemotherapy is the preferred systemic treatment. Even if radical nephrectomy as an up-front strategy did not report a survival benefit, it may be considered to palliate local symptoms and to perform a correct diagnosis.
INTRODUCTION: We describe clinical features and prognostic factors of renal medullary carcinoma (RMC) by performing a pooled analysis of all reported cases since 1995. METHODS: A systematic search was performed to identify all articles describing patients with medullary renal cancer until February 2013. Survivals were estimated using Kaplan-Meier method with 95% confidence intervals and compared across the groups using the log-rank test. The following factors were evaluated using the Cox proportional hazards model: association of extension of disease at diagnosis, response to therapy, and surgical treatment of primary tumour with overall. RESULTS: A total 47 articles were selected; these described 165 patients with RMC plus 1 from our centre. The median age was 21 years and 98% of cases had the sickle cell trait. The mean size of the primary tumours was 6.0 cm, with an involvement of loco-regional lymph nodes in 71% of cases. The overall survival at diagnosis was 4.0 months in metastatic patients and 17.0 months in non-metastatic patients. Patients who received platinum-paclitaxel-gemcitabine had longer control of the disease when compared to topoisomerase inhibitors or targeted therapies. The multivariate analysis confirmed that the advanced stage at diagnosis increased the risk of death of about threefold. CONCLUSION: RMC is a tumour with poorer prognosis; based on these results, platinum-based chemotherapy is the preferred systemic treatment. Even if radical nephrectomy as an up-front strategy did not report a survival benefit, it may be considered to palliate local symptoms and to perform a correct diagnosis.
Authors: Mia A Swartz; John Karth; Dominik T Schneider; Ronald Rodriguez; J Bruce Beckwith; Elizabeth J Perlman Journal: Urology Date: 2002-12 Impact factor: 2.649
Authors: Srinivasa R Prasad; Peter A Humphrey; Christine O Menias; William D Middleton; Marilyn J Siegel; Kyongtae T Bae; Jay P Heiken Journal: Radiographics Date: 2005 Mar-Apr Impact factor: 5.333
Authors: Roula Albadine; Wenle Wang; Noel A Brownlee; Antoun Toubaji; Athanase Billis; Perdram Argani; Jonathan I Epstein; A Julian Garvin; Rima Cousi; Edward M Schaeffer; Christian Pavlovich; George J Netto Journal: J Urol Date: 2009-06-18 Impact factor: 7.450
Authors: Ximing J Yang; Jun Sugimura; Maria S Tretiakova; Kyle Furge; Gregory Zagaja; Mitchell Sokoloff; Michael Pins; Raymond Bergan; David J Grignon; Walter M Stadler; Nicholas J Vogelzang; Bin Tean Teh Journal: Cancer Date: 2004-03-01 Impact factor: 6.860
Authors: Kathryn E Beckermann; Deva Sharma; Shruti Chaturvedi; Pavlos Msaouel; Miguel R Abboud; Yves Allory; Franck Bourdeaut; Julien Calderaro; Aguirre A de Cubas; Vimal K Derebail; Andrew L Hong; Rakhi P Naik; Gabriel G Malouf; Elizabeth A Mullen; Victor E Reuter; Charles W M Roberts; Cheryl L Walker; Christopher G Wood; Michael R DeBaun; Hendrik Van Poppel; Nizar M Tannir; W Kimryn Rathmell Journal: J Oncol Pract Date: 2017-07 Impact factor: 3.840
Authors: Amishi Y Shah; Jose A Karam; Gabriel G Malouf; Priya Rao; Zita D Lim; Eric Jonasch; Lianchun Xiao; Jianjun Gao; Ulka N Vaishampayan; Daniel Y Heng; Elizabeth R Plimack; Elizabeth A Guancial; Chunkit Fung; Stefanie R Lowas; Pheroze Tamboli; Kanishka Sircar; Surena F Matin; W Kimryn Rathmell; Christopher G Wood; Nizar M Tannir Journal: BJU Int Date: 2016-12-09 Impact factor: 5.588
Authors: Pavlos Msaouel; Andrew L Hong; Elizabeth A Mullen; Michael B Atkins; Cheryl Lyn Walker; Chung-Han Lee; Marcus A Carden; Giannicola Genovese; W Marston Linehan; Priya Rao; Maria J Merino; Howard Grodman; Jeffrey S Dome; Conrad V Fernandez; James I Geller; Andrea B Apolo; Najat C Daw; H Courtney Hodges; Marva Moxey-Mims; Darmood Wei; Donald P Bottaro; Michael Staehler; Jose A Karam; W Kimryn Rathmell; Nizar M Tannir Journal: Clin Genitourin Cancer Date: 2018-09-12 Impact factor: 2.872
Authors: Kathryn E Beckermann; Pradeep C Jolly; Ju Y Kim; Jennifer Bordeaux; Igor Puzanov; W Kimryn Rathmell; Douglas B Johnson Journal: J Immunother Cancer Date: 2017-01-17 Impact factor: 13.751
Authors: Darmood Wei; Youfeng Yang; Christopher J Ricketts; Cathy D Vocke; Mark W Ball; Carole Sourbier; Darawalee Wangsa; Danny Wangsa; Rajarshi Guha; Xiaohu Zhang; Kelli Wilson; Lu Chen; Paul S Meltzer; Thomas Ried; Craig J Thomas; Maria J Merino; W Marston Linehan Journal: Genes Chromosomes Cancer Date: 2020-04-17 Impact factor: 5.006